SEC Form 4 · accession 0001237899-15-000021
REGENERON PHARMACEUTICALS, INC. · REGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael S Aberman
Officer — SVP Strategy Investor Relation
Period of report
Feb 23, 2015
Accepted (ET)
Feb 25, 2015 · 4:02 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000872589
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 23, 2015 | M | 7,500 | $30.63 | A | 26,100 | D | |
| Common Stock | Feb 23, 2015 | F | 536 | $427.94 | D | 25,564 | D | |
| Common Stock | Feb 23, 2015 | F | 3,590 | $427.94 | D | 21,974 | D | |
| Common StockF2 | Feb 24, 2015 | S | 600 | $416.31 | D | 21,374 | D | |
| Common StockF3 | Feb 24, 2015 | S | 471 | $417.23 | D | 20,903 | D | |
| Common StockF4 | Feb 24, 2015 | S | 800 | $418.33 | D | 20,103 | D | |
| Common StockF5 | Feb 24, 2015 | S | 1,103 | $419.52 | D | 19,000 | D | |
| Common StockF6 | Feb 24, 2015 | S | 400 | $420.64 | D | 18,600 | D | |
| Common Stock | holding | — | — | — | 407 | I | By 401(k) Plan |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Non-Qualified Stock Option (right to buy)F7 | $30.63 | Feb 23, 2015 | M | 7,500 | D | — | Dec 14, 2020 | Common Stock | 7,500 | 7,500 | D |
Explanation of responses
- F1Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
- F2Represents volume-weighted average price of sales of 600 shares of Company stock on February 24, 2015 at prices ranging from $416.01 to $416.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 24, 2015 at each separate price.
- F3Represents volume-weighted average price of sales of 471 shares of Company stock on February 24, 2015 at prices ranging from $417.08 to $417.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 24, 2015 at each separate price.
- F4Represents volume-weighted average price of sales of 800 shares of Company stock on February 24, 2015 at prices ranging from $418.07 to $418.82. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 24, 2015 at each separate price.
- F5Represents volume-weighted average price of sales of 1,103 shares of Company stock on February 24, 2015 at prices ranging from $419.00 to $419.96. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 24, 2015 at each separate price.
- F6Represents volume-weighted average price of sales of 400 shares of Company stock on February 24, 2015 at prices ranging from $420.30 to $420.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on February 24, 2015 at each separate price.
- F7The stock option award vests in four equal annual installments, commencing one year after the date of grant.